se of the Placental Growth Factor (PlGF) test in pregnant women with Chronic Hypertension to evaluate superimposed Pre-eclampsia

Not Applicable

• Conditions: Essential Hypertension; Pre-eclampsia

• Registration Number: RBR-2zx5y9r
• Lead Sponsor: Hospital da Mulher Professor Doutor José Aristodemo Pinotti - Centro de Atenção Integral à Saúde da Mulher

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-07-09
• Last Update Posted: 22 July 2024
• Study Completion: 2025-07-01

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

All pregnant women diagnosed with chronic hypertension and clinical suspicion of superimposed preeclampsia (due to worsening blood pressure control); age over 18 years; gestacional age over 20 weeks; exacerbated weight gain; emergence or worsening of proteinuria; signs of placental insufficiency after 20 weeks of gestation

Exclusion Criteria

HELLP syndrome; eclampsia; signs of imminent eclampsia; hypertensive crisis, when systolic blood pressure =160 and/or diastolic blood pressure =110mmHg; acute fetal distress

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduce frequency of prematurity related to superimposed pre-eclampsia.

Secondary Outcome Measures

Name	Time	Method
Implementing the use of PlGF will reduce the need for hospitalization and costs in chronic hypertension cases.;Implementing the use of PlGF will reduce the frequency of cesarean births and severe pré-eclâmpsia.;Implementing the use of PlGF will improve the perinatal outcome of superimposed preeclampsia cases.;The groups will be similar in sociodemographic characteristics and background.